Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 5 studies | 31% ± 14% | |
astrocyte | 4 studies | 27% ± 11% |
Insufficient scRNA-seq data for expression of CHST1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 93% | 4042.83 | 2449 / 2642 | 97% | 38.49 | 686 / 705 |
thymus | 100% | 2883.37 | 651 / 653 | 87% | 28.04 | 524 / 605 |
ovary | 82% | 618.12 | 147 / 180 | 85% | 21.50 | 365 / 430 |
lung | 72% | 506.38 | 415 / 578 | 40% | 4.90 | 466 / 1155 |
adrenal gland | 28% | 247.04 | 73 / 258 | 75% | 58.69 | 173 / 230 |
ureter | 0% | 0 | 0 / 0 | 100% | 27.36 | 1 / 1 |
spleen | 95% | 976.12 | 229 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 1356.44 | 1242 / 1335 | 0% | 0 | 0 / 0 |
breast | 22% | 123.82 | 102 / 459 | 69% | 17.88 | 776 / 1118 |
kidney | 40% | 304.91 | 36 / 89 | 39% | 5.50 | 347 / 901 |
uterus | 42% | 222.85 | 72 / 170 | 36% | 5.18 | 163 / 459 |
pancreas | 4% | 17.12 | 12 / 328 | 69% | 7.09 | 122 / 178 |
esophagus | 20% | 106.13 | 289 / 1445 | 45% | 7.93 | 83 / 183 |
muscle | 46% | 602.54 | 369 / 803 | 0% | 0 | 0 / 0 |
heart | 42% | 230.44 | 364 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 38% | 8.17 | 17 / 45 |
stomach | 10% | 45.78 | 35 / 359 | 28% | 2.34 | 79 / 286 |
skin | 4% | 22.89 | 66 / 1809 | 29% | 3.83 | 138 / 472 |
bladder | 14% | 90.14 | 3 / 21 | 18% | 1.93 | 89 / 504 |
intestine | 12% | 63.25 | 119 / 966 | 16% | 1.32 | 84 / 527 |
prostate | 27% | 135.11 | 66 / 245 | 1% | 0.03 | 3 / 502 |
adipose | 27% | 145.19 | 331 / 1204 | 0% | 0 | 0 / 0 |
liver | 4% | 23.53 | 10 / 226 | 22% | 2.66 | 90 / 406 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.67 | 4 / 29 |
eye | 0% | 0 | 0 / 0 | 4% | 0.17 | 3 / 80 |
peripheral blood | 0% | 2.01 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042339 | Biological process | keratan sulfate metabolic process |
GO_0006044 | Biological process | N-acetylglucosamine metabolic process |
GO_0006954 | Biological process | inflammatory response |
GO_0005976 | Biological process | polysaccharide metabolic process |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0018146 | Biological process | keratan sulfate biosynthetic process |
GO_0006012 | Biological process | galactose metabolic process |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016020 | Cellular component | membrane |
GO_0045130 | Molecular function | keratan sulfotransferase activity |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0001517 | Molecular function | N-acetylglucosamine 6-O-sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CHST1 |
Protein name | Carbohydrate sulfotransferase 1 (Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 1) (GST-1) (Keratan sulfate Gal-6 sulfotransferase) (KS6ST) (KSGal6ST) (KSST) (EC 2.8.2.21) |
Synonyms | |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of internal galactose (Gal) residues of keratan. Cooperates with B4GALT4 and B3GNT7 glycosyltransferases and CHST6 sulfotransferase to construct and elongate disulfated disaccharide unit [->3(6-sulfoGalbeta)1->4(6-sulfoGlcNAcbeta)1->] within keratan sulfate polymer . Has a preference for sulfating keratan sulfate, but it also transfers sulfate to the unsulfated polymer . Involved in biosynthesis of phosphacan, a major keratan sulfate proteoglycan in the developing brain (By similarity). Involved in biosynthesis of 6-sulfoGalbeta-containing O-linked glycans in high endothelial venules of lymph nodes. May act in a synergistic manner with CHST4 to generate sialyl 6',6-disulfo Lewis X motif, a recognition determinant for immune cell receptors implicated in leukocyte trafficking . Catalyzes sulfation of N-acetyllactosamine (LacNAc) oligosaccharides with highest efficiency for sialylated LacNAc structures . . |
Accessions | O43916 ENST00000308064.7 |